Compare Abeona Therapeutics Inc (ABEO) vs Omnicom Group Inc. (OMC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Omnicom Group Inc. — how do they compare? Abeona Therapeutics Inc trades at $6.77 (market cap $373.32M), while Omnicom Group Inc. trades at $78.84 (market cap $23.04B). The key difference: Omnicom Group Inc. is far larger — about 61.7× Abeona Therapeutics Inc's market cap, and Omnicom Group Inc. pays a 3.96% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | OMC | |
|---|---|---|
Market Cap | $373.32M | $23.04B |
Sector | Health | Media |
52-Week High | $7.23 | $85.80 |
52-Week Low | $4.17 | $67.27 |
Enterprise Value | $228.22M | $30.27B |
Dividend Yield | — | 3.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
OMC trades at $80.84, up 2.82% today, with a bullish technical outlook supported by moving averages and a consensus price target of $105.75. Recent Q1 2026 earnings beat expectations with EPS of $1.90 versus $1.82 expected, while revenue grew to $17.27B in 2025. The company announced new partnerships with IBM and Netflix, enhancing its media agency footprint, and declared a $0.80 dividend payable in July 2026.
The stock presents value with a low P/E of 12.16 and P/S of 0.93, but net income turned negative in 2025, posing a risk. Analyst sentiment is mixed with 32% buy ratings, reflecting optimism about growth initiatives against profitability concerns. Investors should weigh the attractive valuation and strong cash flow against execution risks in a competitive advertising market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →
